NextCure delays LNCB74 trial data, expects SIM0505 results in Q2 2026 Jan 23, 2026 07:01AM
NextCure Inc. (NXTC) files for 2.52M share offering by selling stockholders Nov 26, 2025 04:03PM
Ladenburg Thalmann Upgrades NextCure Inc. (NXTC) to Buy Nov 7, 2025 07:22AM
NextCure, Inc. (NXTC) Misses Q3 EPS by 277c Nov 5, 2025 05:58PM
NextCure reports preclinical data on bone disease treatment Jul 24, 2025 04:38PM


Jul 15, 2025 09:01AM NextCure Inc. (NXTC) PT Lowered at Piper Sandler Following the Reverse Stock Split
Jun 16, 2025 07:07AM NextCure (NXTC) and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
Mar 17, 2025 10:19AM H.C. Wainwright Reiterates Buy Rating on NextCure Inc. (NXTC)
Jan 10, 2025 08:07AM NextCure Inc. (NXTC) doses first patient in Phase 1 study of LNCB74
Dec 10, 2024 08:05AM NextCure Inc. (NXTC) Announces Acceptance of IND Application for LNCB74
Nov 19, 2024 08:05AM NextCure Inc. (NXTC): Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfec
Nov 8, 2024 06:23AM NextCure, Inc. (NXTC) Misses Q3 EPS by 6c
Nov 5, 2024 04:05PM NextCure Inc. (NXTC) Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
Sep 16, 2024 08:05AM NextCure Inc. (NXTC) Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab
Aug 2, 2024 03:59AM NextCure, Inc. (NXTC) Misses Q2 EPS by 17c